亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

3-Hydroxy-Propanamine Derived Neuronal Reuptake Inhibitors

總結: Antidepressants such as Prozac, Paxil and Zoloft, are characterized by an ability to selectively block reuptake of serotonin (5-HT). Selective NE-reuptake inhibitor antidepressants such as Tomoxetine and Vivalan have also been developed. Effexor and Serzone have been termed SNRI antidepressants because they inhibit 5-HT and NE reuptake with similar potency. However, these present drugs are ineffective to some patients. Only new generation of drugs possess reuptake inhibition profile different from those currently known can solve the problem.

The invention relates to the new class of antidepressant compounds, which exhibit synaptosomal reuptake inhibition of neurotransmitters such as serotonin (5-HT), norephinephrine (NE), and dopamin (DA) simultaneously. These new compounds possess special reuptake inhibition profile. The antidepressant properties of these compounds were assayed. The best of these new compounds bind to the transporter protein 175 times stronger than serotonin itself. These compounds will therefore effectively block synaptosomal reuptake of serotonin.

技術優勢: 1. Comparatively reduced therapeutic dosages of antidepressant compounds
2. Less side effects
3. More effective
4. Wide range of usage

附加資料: Patent Number: US6069177A
Application Number: US1997889357A
Inventor: Carlier, Paul R. | Richelson, Elliott | Lo, Ching Kam | Lo, Man Chu
Priority Date: 8 Jul 1997
Priority Number: US6069177A
Application Date: 8 Jul 1997
Publication Date: 30 May 2000
IPC Current: C07C021528
US Class: 514652 | 564349
Assignee Applicant: The Hong Kong University of Science & Technology
Title: 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
Usefulness: 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
Summary: USE The derivative represents a kind of new-type mental state therapeutic medicine as antidepressant.
Novelty: 3-hydroxyl-propylamide derived nerve cell reabsorption inhibitor useful as a new-type mental state therapeutic medicine as a antidepressant

欲了解更多信息，請點擊這裡